Laboratory and human studies showed that lidocaine reduced the levels of the tumor markers IL-1, TNF-α and IL-8 and had a direct effect on cancer cells via blockade of voltage-gated sodium channels or other mechanisms. Here, CXCL8 is linked to cancer.